Revive Therapeutics Ltd. (RVVTF)
| Previous Close | 0.0204 |
| Open | 0.0190 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0190 - 0.0210 |
| 52 Week Range | 0.0160 - 0.0570 |
| Volume | |
| Avg. Volume | 289,740 |
| Market Cap | 6.81M |
| Beta (5Y Monthly) | -0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | May 28, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an ora
- GlobeNewswire
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on
- GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an invest
